Meeting Impression | Outcomes of GLP-1 RA in Diabetes & CVD
See below to download the Meeting Impression
This EBAC-accredited symposium was held during ESC 2018 in Munich, Germany. Prof. Deanfiel, dr. Knop and prof. Rydén presented evidence on the cardiovascular (CV) risk associated with type 2 diabetes (T2DM). Acknowledging that T2DM is a state of enhanced CV risk, in combination with the advent of novel antiglycemic agents that also provide CV benefit, paves the way for a new, broader approach of T2DM management. Rather than focusing on glucose lowering, management needs to be directed at reducing and delaying CV complications in T2DM patients. In the symposium, it was discussed how recent outcome trial data with GLP-1RA can be translated to clinical practice.
This is a summary of the PACE symposium entitled 'Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice?', held during ESC in Munich, Germany, on August 27, 2018.
The educational objectives of the symposium were to:
- Understand the Association between CV risk and T2DM
- Acknowledge that T2DM is a state of enhanced CV risk
- Recognize novel antiglycemic agents that also provide CV benefit
- Explore a broader approach of T2DM management
- Understand that management needs to be directed at reducing and delaying CV complications in T2DM
- Discuss how recent outcome trial data with GLP-1RA can be translated to clinical practice
Prof. John E Deanfield (London, United Kingdom): Diabetes & CVD: Time for a multifactorial approach
Dr. Filip K. Knop, MD, PhD (Copenhagen, Denmark): GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control
Lars Rydén, MD (Stockholm, Sweden): Translating GLP-1 trial outcomes to cardiology practice: Which patients will benefit?
This symposium was supported by an unrestricted educational grant received from Novo Nordisk